2. Antibody-drug Conjugate/ADC Related Anti-infection
  3. ADC Payload Bacterial Antibiotic
  4. Sandramycin

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity.

For research use only. We do not sell to patients.

Sandramycin

Sandramycin Chemical Structure

CAS No. : 100940-65-6

Size Price Stock Quantity
1 mg Get quote 3 - 4 Weeks 4 - 5 weeks 5 - 6 weeks 2 - 3 weeks
5 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Sandramycin Related Antibodies

Top Publications Citing Use of Products

View All ADC Payload Isoform Specific Products:

View All Isoforms
Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity[1][2][3].

IC50 & Target[1]

Traditional Cytotoxic Agents

 

Cellular Effect
Cell Line Type Value Description References
786-0 IC50
8 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
10.1016/S0960-894X(97)00129-7
B16 IC50
0.4 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)
The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)
10.1016/S0960-894X(97)00129-7
BT-549 IC50
1 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)
The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)
10.1016/S0960-894X(97)00129-7
EBC-1 IC50
1.4 nM
Compound: Sandramycin
Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
[PMID: 37307297]
H322 IC50
20 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)
10.1016/S0960-894X(97)00129-7
HL-60 IC50
80 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)
The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)
10.1016/S0960-894X(97)00129-7
HT-29 IC50
1 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)
10.1016/S0960-894X(97)00129-7
IGROV-1 IC50
1.6 nM
Compound: Sandramycin
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
[PMID: 37307297]
L1210 IC50
0.02 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)
The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)
10.1016/S0960-894X(97)00129-7
MCF7 IC50
300 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)
The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)
10.1016/S0960-894X(97)00129-7
MOLT-4 IC50
0.7 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)
The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)
10.1016/S0960-894X(97)00129-7
OVCAR-3 IC50
1 nM
Compound: Sandramycin
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
[PMID: 37307297]
OVCAR-3 IC50
4 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)
The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)
10.1016/S0960-894X(97)00129-7
PC-3 IC50
0.2 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)
The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)
10.1016/S0960-894X(97)00129-7
SK-MEL-28 IC50
1 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)
The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)
10.1016/S0960-894X(97)00129-7
SiHa IC50
0.3 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)
The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)
10.1016/S0960-894X(97)00129-7
UCLA P-3 IC50
10 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)
10.1016/S0960-894X(97)00129-7
In Vitro

Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for Bacillus subtilis (Rec+) A22508-2, B. subtilis (Rec-) A22509-2-2, Staphylocccus aureus 209P-A9497, S. aureus (echinomycin-resistant) A9628, Streptococcus faecalis A96 1 1, Escherichia coli A151 19 and E. coli (actinomycin-sensitive) A21780 (AS-19), respectively[1].
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC50 values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sandramycin Related Antibodies
In Vivo

Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CDF1 female mice injected with leukemia P388 cells[1]
Dosage: 0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg
Administration: Intraperitoneal injection; daily; for 5 days
Result: Was moderately active in vivo against leukemia P388 in mice.
Molecular Weight

1221.32

Formula

C60H76N12O16
CAS No.
SMILES

CC(C)[C@@H](C(OC[C@@H](NC(C1=C(O)C=C(C=CC=C2)C2=N1)=O)C3=O)=O)N(C)C(CN(C)C(CNC([C@@H]4CCCCN4C([C@@H](COC([C@H](C(C)C)N(C)C(CN(C)C(CNC([C@H]5N3CCCC5)=O)=O)=O)=O)NC(C6=C(O)C=C(C=CC=C7)C7=N6)=O)=O)=O)=O)=O
Structure Classification
Initial Source

Nocardioides sp.
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sandramycin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sandramycin100940-65-6ADC PayloadBacterialAntibioticADC CytotoxinDNAintercalatordepsipeptideantibioticantitumorGram-positivebis-intercalationCytotoxinADCInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sandramycin
Cat. No.:
HY-19829
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.